• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Advertisement

New Delhi Feb. 9 Ranbaxy Laboratories Ltd said it has bagged the US Food and Drug Administration approval to make and sell five strengths of Sertraline Hydrochloride tablets.

In an official statement, the company said that the Office of Generic Drugs, US FDA, had determined its formulation to be bioequivalent to Pfizer's Zoloft, prescribed in the treatment of major depressive and anxiety disorders in adults. The company has approval for 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg tablets.

"Ranbaxy now offers both solid and liquid dosage forms for this molecule that has established its utility and value in major depressive disorder. This product formulation will be launched immediately," said Mr Jim Meehan, Vice-President, Sales and Marketing of Ranbaxy's Florida based subsidiary.

The total annual market sales for Sertraline Hydrochloride Tablets for 2006 were at $3.07 billion, Ranbaxy said.

More Stories on : Announcements | Pharmaceuticals | Ranbaxy Laboratories Ltd

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
ONGC suspends drilling campaign in Mahanadi basin

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line